INAB · In8bio, Inc.
$1.11
-0.08 (-6.72%)
At close · Jul 28
Going-concern doubt
— flagged May 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company’s business strategy, its existing cash of $21.9 million as of March 31, 2026 is not anticipated to fund the Company’s projected operating expenses and capital expenditure requirements for a period of at least 12 months from the date of issuance of these condensed financial statements, and accordingly, there is substantial doubt about the Company’s ability to continue to operate as a going concern.”View the 10-Q filed May 7, 2026
Market Cap
$10.93M
Shares
9.85M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$19.44M
+36.1%
FY2025
Diluted EPS
-$4.44
+74%
FY2025
Operating Cash Flow
-$12.71M
+47.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $9.85M | $10.21M | $16.96M | $16.83M | $14.06M | $7.35M | |
| $9.62M | $9.65M | $12.64M | $13.51M | $14.46M | $7.31M | |
| $19.47M | $19.86M | $30.67M | $30.34M | $28.52M | $14.65M | |
| -$18.98M | -$19.44M | -$30.44M | -$30.34M | -$28.52M | -$14.65M | |
| $487K | $421K | $230K | — | — | — | |
| — | -$19.44M | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | |
| -$18.98M | -$19.44M | -$30.44M | -$30.01M | -$28.52M | -$14.65M | |
| -$25.15M | — | — | — | — | -$14.65M | |
| USD/shares | — | -$4.44 | -$17.10 | -$30.00 | -$40.80 | — |
| USD/shares | — | -$4.44 | -$17.10 | -$30.00 | -$40.80 | — |
| shares | — | 4.37M | 1.78M | 995.5K | 698.93K | 332.32K |
| shares | — | 4.37M | 1.78M | 995.5K | 698.93K | 332.32K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Peer median 0.04×
Peer medians compare against the 196 similar-size Biotechnology companies (of 522 listed).